Orexo inks $585M drug pact with J&J

Sweden's Orexo is pocketing $10 million from an upfront payment it will reap as part of a three-year, $585 million development pact with J&J's drug arm. The collaboration centers on preclinical small molecule drug candidates Orexo has been working on for asthma, COPD as well as other inflammatory conditions. And Orexo says it stands to gain more than $21 million in research funding from Ortho-McNeil-Janssen Pharmaceuticals and Janssen Pharmaceutica. Orexo release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.